Skin cancer vaccine BLA submitted by...?
This event asks whether Moderna and Merck, or the FDA, will officially announce that a Biologics License Application (BLA) for intismeran autogene (also called mRNA-4157 or V940, the individualized skin cancer vaccine) has been submitted to the FDA. It also resolves Yes if the FDA has accepted such an application for review, or has approved the product, by the deadline. The key point is that plans and expected timing do not count. The submission must already have happened when the statement is made.
Leading right now: June 30, 2027? 80%, March 31, 2027 72%.
| Market | Chance of yes | Deadline |
|---|---|---|
| Skin cancer vaccine BLA submitted by June 30, 2027? | 80.5% | Jul 1, 2027, 3:59 UTC |
| Skin cancer vaccine BLA submitted by March 31, 2027? | 72.5% | Apr 1, 2027, 3:59 UTC |
Odds read from Polymarket at 22:18 UTC on Nov 21, 2026. $159K traded so far, $516 in the last 24 hours.
How this market resolves
Yes: Yes if, by the deadline, Moderna, Merck, the FDA, or their authorized representatives officially announce that a BLA for intismeran autogene has been submitted to the FDA, or that the FDA has accepted one for review. Yes also if the FDA approves the product by the deadline, even if no submission was announced separately. An original BLA or a resubmission after FDA action qualifies, for any indication.
No: No if none of these things has happened by the deadline. That means no announced BLA submission, no announced FDA acceptance for review, and no FDA approval. Statements of intent, plans, guidance, or expected filing timing do not make it Yes.
When it really ends
June 30, 2027, 11:59 PM ET for the June market. On that date New York is on daylight time (UTC-4), so this is 2027-07-01 03:59 UTC. The data's endDate matches this. The March market's rules text was not provided. Its title and endDate point to March 31, 2027, 11:59 PM ET, which is 2027-04-01 03:59 UTC. This assumes the same rules apply with only the date changed.
What counts
- An official announcement from Moderna, Merck, or the FDA that a BLA has been submitted
- An official announcement that the FDA has accepted a BLA for review
- FDA approval of intismeran autogene by the deadline, even with no separate submission announcement
- A resubmission of a BLA after FDA action
- A BLA for any indication, not only the one studied in INTerpath-001
- The product under any later brand or nonproprietary name, or a renamed or modified version the companies or FDA identify as the same program
What does not count
- Statements of intent, plans, guidance, or expected timing for a filing
- Trial results alone, including positive Phase 3 INTerpath-001 data, without a submission
- Applications to regulators other than the FDA, or applications that are not BLAs
- Announcements from parties who are not the company, the FDA, or their authorized representatives (credible-reporting consensus may be used, but only for a submission that has actually occurred)
- Other Moderna or Merck products or unrelated cancer vaccines
Fine print people miss
- FDA approval by the deadline resolves Yes even if no submission was ever separately disclosed.
- The rules allow a consensus of credible reporting as a resolution source, not only official statements.
- The rules do not say clearly whether the announcement itself must come by the deadline or only the submission. Traders should not assume the two can be separated.
- The rules do not address partial or rolling submissions, so such a case would be ambiguous.
- The March 31, 2027 market's rules text was not provided. Check the rules on that market's page, since the deadline there is earlier.
What moves the price
- Phase 3 INTerpath-001 results being reported, especially positive efficacy results, which would make a filing more likely
- Company statements giving a firm filing timeline, which would push toward Yes, or delaying it, which would push toward No
- Reports of FDA meetings or feedback on what data a filing needs
- Trial delays, extended follow-up, or safety concerns, which would push toward No
- An announcement that a BLA has been submitted or accepted, which would settle the market as Yes
Put a bot on this market
A PROWL bot reads the news around the clock, judges each post against these exact rules, and trades inside the limits you set. It starts in paper mode.
Questions people ask
What is intismeran autogene?
It is the individualized neoantigen therapy developed by Moderna and Merck, also known as mRNA-4157 or V940. It is tested in the Phase 3 INTerpath-001 trial (NCT05933577). The rules treat any later brand name or renamed version of the same program as the same product.
Does a BLA have to be submitted for this market to resolve Yes?
No. An official announcement of FDA acceptance for review also counts. So does FDA approval by the deadline, even if no submission was separately announced.
Does a company saying it plans to file count?
No. The submission must already have occurred when the statement is made. Statements of intent, plans, guidance, or expected timing do not qualify.
What is the deadline for the June market?
It is June 30, 2027 at 11:59 PM ET, which is 2027-07-01 03:59 UTC. The rules text governs, and here it agrees with the data's end date.
Does a filing for a different indication count?
Yes. The rules say the application may cover any indication. It must be a BLA seeking FDA licensure of intismeran autogene.
Who can make a qualifying announcement?
The company submitting the BLA, the FDA, or their authorized representatives. A consensus of credible reporting may also be used to resolve the market.
More Tech markets explained
Written from the market's own rules text on Nov 17, 2026. If the rules on Polymarket differ from this page, the rules on Polymarket govern.